Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Shares Outstanding (Weighted Average) (2017 - 2020)

Monopar Therapeutics (MNPR) has disclosed Shares Outstanding (Weighted Average) for 4 consecutive years, with $10.8 million as the latest value for Q3 2020.

  • Quarterly Shares Outstanding (Weighted Average) rose 16.15% to $10.8 million in Q3 2020 from the year-ago period, while the trailing twelve-month figure was $10.8 million through Sep 2020, up 16.15% year-over-year, with the annual reading at -$0.83 for FY2022, 13.7% down from the prior year.
  • Shares Outstanding (Weighted Average) hit $10.8 million in Q3 2020 for Monopar Therapeutics, up from $10.6 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $10.8 million in Q3 2020 to a low of $8.3 million in Q1 2017.
  • Historically, Shares Outstanding (Weighted Average) has averaged $9.4 million across 4 years, with a median of $9.3 million in 2018.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): changed 0.0% in 2019 and later rose 16.15% in 2020.
  • Year by year, Shares Outstanding (Weighted Average) stood at $8.8 million in 2017, then increased by 5.8% to $9.3 million in 2018, then increased by 0.32% to $9.3 million in 2019, then increased by 15.78% to $10.8 million in 2020.
  • Business Quant data shows Shares Outstanding (Weighted Average) for MNPR at $10.8 million in Q3 2020, $10.6 million in Q2 2020, and $10.6 million in Q1 2020.